Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

pharmafile | November 4, 2020 | News story | Research and Development BMS, deucravacitinib, plaque psoriasis 

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib met both its primary and secondary goals in the treatment of moderate to severe plaque psoriasis.

According to the findings, 666 participants were randomised to receive either a daily 6mg dose of the drug or placebo. It was found that a higher number of patients receiving deucravacitinib achieved an improvement of at least 75% on the Psoriasis Area and Severity Index (PASI 75), as well as a static Physician’s Global Assessment (sPGA) score of clear or almost clear (sPGA 0 or 1) 16 weeks following initial dosing. Based on this, the study met both its co-primary goals.

Deucravacitinib also outclassed Amgen’s Otezla (apremilast) in the study, with a greater proportion of patients achieving PASI 75 and sPGA 0/1 with the former than the latter after 16 weeks of treatment, hitting the secondary endpoint of the trial.

“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective oral therapies. This makes the positive topline results for deucravacitinib in the POETYK PSO-1 trial exciting for the psoriasis community,” remarked Dr April Armstrong, Associate Dean and Professor of Dermatology at the University of Southern California. “These findings indicate deucravacitinib has the potential to be a new treatment option for people living with psoriasis and may provide clinically meaningful improvements with the convenience of oral administration.”

BMS confirmed that it will share full results from the study at an upcoming medical event, once it has conducted a full evaluation alongside principal investigators.

Matt Fellows

Related Content

BMS follow-up data sees long-term survival for melanoma patients

Bristol Myers Squibb (BMS) has announced follow-up data from their Phase III CheckMate-067 clinical trial, …

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS …


Canadian approval for Reblozyl for transfusion-dependent anaemia in beta-thalassemia patients

Bristol Myers Squibb and Acceleron have managed to secure regulatory approval in Canada for Reblozyl …

Latest content